Abbvie Inc (ABBV)

$252.74 -1.91 (-0.75%)
Market Cap 450.11B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 25.62
Forward PE 18.28
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 7,578,576
Avg Vol 7,326,928
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 76%
Beta 0.30
Analysts Strong Sell
Price Target $254.72

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 8 at 11:25 PM
$SLS $ABBV this $2.6B manipulated mcap will be worth $40B to big pharma $LLY $ABBV $PFE the instant Gps Phase 3 registrational results are announced. $2.6B /$13.5 per share will be worth $40B / $200 per share all day.
0 · Reply
FutureCapitall
FutureCapitall Jul. 8 at 10:38 PM
$ABBV $LLY $SLS Been saying for a while: if the therapy is truly delivering 0 toxicity, 0 safety issues, great QOL, and a curative-style maintenance setup, the price ceiling could be a lot higher — maybe around $480K per patient per year over 3+ years. That’s the kind of value case the market notices.
2 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 8 at 8:59 PM
$ABBV $LLY $SLS 😉 Greg my Long Brother, I have been saying for a while you might want to raise the pricing to about $480K per patient per year for 3 year plus for only 0 Toxicity, 0 Safety issues, Excellent QOL CURATIVE maintenance schedule and Dr. Angelos just alluded to that in his Linkedln post. “Market Access: Ignores our extensive unannounced pricing and reimbursement architecture.” 👇 ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 8 at 8:42 PM
$SLS Phase 3 Results are now Imminent - Gps will treat upwards of 50,000 AML Remission patients each year $280K Rev Per Patient, compounded dosing to relapse revenue, Tens of Billions of dollars in Real Revenue worth Every nickel of $40B to Big Pharma $LLY $ABBV Day 62 Since the 78th Event
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 8 at 6:20 PM
$SLS $ABBV Day 58 / Day 62 22 Day Event Rate
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 8 at 7:26 AM
$SLS $ABBV Every day is another Short Pull on the Trigger in their Psychotic game of Russian Roulette - one day soon its cherry pie time. $18 /$20 by Friday - they can’t risk being out short when the 80th Event is announced, they know, the market knows - the imminent Gps Topline Phase 3 results are worth $40B to big pharma 1,800% more than the current short rigged share price.
0 · Reply
JInvestTrade
JInvestTrade Jul. 8 at 5:33 AM
$SENS $DXCM $ABBV $TNDM $PODD https://lnkd.in/p/gEzezxjR
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Jul. 8 at 4:21 AM
$PFE $MRK $LLY $ABBV $BMY https://chinauncensored.substack.com/p/big-pharma-is-running-drug-trials
0 · Reply
SwingTraderPro1
SwingTraderPro1 Jul. 7 at 11:51 PM
$ABBV The trend has been relentless, with buyers continuing to defend every pullback and push price higher. That said, when a stock gets this extended near highs, caution becomes part of the plan - strong moves can still require a reset. For now, the structure remains healthy and the trend is intact. The key level I’m watching is ~$244. A break below that could signal a deeper retracement and a shift in short-term momentum. Until then, the trend stays in control - but risk management matters most when everyone starts chasing strength.
0 · Reply
CosmicMiner
CosmicMiner Jul. 7 at 10:17 PM
$ABBV is officially an unstoppable beast! Up and up for eternity. This price action is an absolute masterpiece. While chasing these violent impulses at macro highs always calls for caution, you can't argue with a perfectly healthy, surging uptrend. Big money is clearly locked in. Keep your eyes on the chart-as long as we hold above $244, the bullish structure remains fully intact. Anything below that, and we talk about a deeper pullback.
0 · Reply
Latest News on ABBV
Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 1 day ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie says Q2 EPS to include unfavorable impact of 17c

2026-07-06T20:20:39.000Z - 2 days ago

AbbVie says Q2 EPS to include unfavorable impact of 17c

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

2026-07-06T20:20:19.000Z - 2 days ago

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

2026-07-06T20:20:13.000Z - 2 days ago

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

AbbVie says Tepkinly combo approved by EC for lymphoma treatment

2026-07-06T17:50:14.000Z - 2 days ago

AbbVie says Tepkinly combo approved by EC for lymphoma treatment

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 2 days ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie price target raised to $300 from $275 at HSBC

2026-07-06T14:20:07.000Z - 2 days ago

AbbVie price target raised to $300 from $275 at HSBC

AbbVie price target raised to $265 from $240 at Cantor Fitzgerald

2026-07-06T11:05:07.000Z - 2 days ago

AbbVie price target raised to $265 from $240 at Cantor Fitzgerald

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

2026-06-30T14:05:22.000Z - 8 days ago

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

MRK

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 8 days ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial

2026-06-29T20:20:34.000Z - 9 days ago

AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial

GMAB

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 9 days ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie announces CHMP opinion recommending approval of upadacitinib for AA

2026-06-29T09:20:22.000Z - 9 days ago

AbbVie announces CHMP opinion recommending approval of upadacitinib for AA

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 9 days ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 9 days ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

2026-06-26T20:55:10.000Z - 12 days ago

AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 12 days ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 12 days ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 12 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 14 days ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 14 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

2026-06-23T12:54:44.000Z - 15 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

2026-06-23T12:22:00.000Z - 15 days ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

APGE

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 15 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Apogee Therapeutics moved to No Rating at BofA

2026-06-23T11:29:50.000Z - 15 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE

AbbVie price target raised to $273 from $265 at Canaccord

2026-06-23T11:04:51.000Z - 15 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 15 days ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 15 days ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 16 days ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 16 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 16 days ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 16 days ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 16 days ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 16 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 16 days ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 16 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 16 days ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 18 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 19 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 20 days ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 22 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 26 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 27 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 4 weeks ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 4 weeks ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 5 weeks ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 5 weeks ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 6 weeks ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 6 weeks ago

US FDA approves AbbVie's rare blood cancer drug

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 6 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 6 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 2 months ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 2 months ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 2 months ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 2 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 2 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 2 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 2 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 2 months ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 2 months ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 8 at 11:25 PM
$SLS $ABBV this $2.6B manipulated mcap will be worth $40B to big pharma $LLY $ABBV $PFE the instant Gps Phase 3 registrational results are announced. $2.6B /$13.5 per share will be worth $40B / $200 per share all day.
0 · Reply
FutureCapitall
FutureCapitall Jul. 8 at 10:38 PM
$ABBV $LLY $SLS Been saying for a while: if the therapy is truly delivering 0 toxicity, 0 safety issues, great QOL, and a curative-style maintenance setup, the price ceiling could be a lot higher — maybe around $480K per patient per year over 3+ years. That’s the kind of value case the market notices.
2 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 8 at 8:59 PM
$ABBV $LLY $SLS 😉 Greg my Long Brother, I have been saying for a while you might want to raise the pricing to about $480K per patient per year for 3 year plus for only 0 Toxicity, 0 Safety issues, Excellent QOL CURATIVE maintenance schedule and Dr. Angelos just alluded to that in his Linkedln post. “Market Access: Ignores our extensive unannounced pricing and reimbursement architecture.” 👇 ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 8 at 8:42 PM
$SLS Phase 3 Results are now Imminent - Gps will treat upwards of 50,000 AML Remission patients each year $280K Rev Per Patient, compounded dosing to relapse revenue, Tens of Billions of dollars in Real Revenue worth Every nickel of $40B to Big Pharma $LLY $ABBV Day 62 Since the 78th Event
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 8 at 6:20 PM
$SLS $ABBV Day 58 / Day 62 22 Day Event Rate
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 8 at 7:26 AM
$SLS $ABBV Every day is another Short Pull on the Trigger in their Psychotic game of Russian Roulette - one day soon its cherry pie time. $18 /$20 by Friday - they can’t risk being out short when the 80th Event is announced, they know, the market knows - the imminent Gps Topline Phase 3 results are worth $40B to big pharma 1,800% more than the current short rigged share price.
0 · Reply
JInvestTrade
JInvestTrade Jul. 8 at 5:33 AM
$SENS $DXCM $ABBV $TNDM $PODD https://lnkd.in/p/gEzezxjR
0 · Reply
LQQKER_INSIDER
LQQKER_INSIDER Jul. 8 at 4:21 AM
$PFE $MRK $LLY $ABBV $BMY https://chinauncensored.substack.com/p/big-pharma-is-running-drug-trials
0 · Reply
SwingTraderPro1
SwingTraderPro1 Jul. 7 at 11:51 PM
$ABBV The trend has been relentless, with buyers continuing to defend every pullback and push price higher. That said, when a stock gets this extended near highs, caution becomes part of the plan - strong moves can still require a reset. For now, the structure remains healthy and the trend is intact. The key level I’m watching is ~$244. A break below that could signal a deeper retracement and a shift in short-term momentum. Until then, the trend stays in control - but risk management matters most when everyone starts chasing strength.
0 · Reply
CosmicMiner
CosmicMiner Jul. 7 at 10:17 PM
$ABBV is officially an unstoppable beast! Up and up for eternity. This price action is an absolute masterpiece. While chasing these violent impulses at macro highs always calls for caution, you can't argue with a perfectly healthy, surging uptrend. Big money is clearly locked in. Keep your eyes on the chart-as long as we hold above $244, the bullish structure remains fully intact. Anything below that, and we talk about a deeper pullback.
0 · Reply
inv1ncible
inv1ncible Jul. 7 at 7:52 PM
$VKTX come on $ABBV
0 · Reply
SGL_FGHI
SGL_FGHI Jul. 7 at 3:37 PM
$TGTX With patent cliff issues and competition, BIG PHARMA keeping its money in the bank will not ensure its success and prosperity. Regarding TGTX, the BP with leadership that has vision, creativity, and willingness to act will be victorious. The other shareholders could then be saying to their leadership time is money and – How the heck did you miss that which was right before our and - most importantly - your eyes! $ABBV $JNJ $BMY
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 7 at 3:31 PM
$SLS $ABBV 78th Event was announced on May 11 -- - 22 Days Per Event -- it is now 58 DAYS since the 78th -- Friday it’ll Be 61 / Monday it’ll be 64 if we get that Far. Buy and Hold. This $13.10 stock is going to be a $130 stock and climbing. Current $2.5B Mcap is about to 10X.
0 · Reply
biolover
biolover Jul. 7 at 3:11 PM
$LLY black swan could be coming. $VKTX is $ABBV opportunity to catch up. CEO knows that. VKTX CEO needs money now.
0 · Reply
biolover
biolover Jul. 7 at 2:33 PM
$VKTX $ABBV jet was in SD. That is primary item that institutions care about. Most know my ass about drugs 😂 Someone is buying puts on $NVO for 7-17. Let us see if amycretin will save them 😂
1 · Reply
peloswing
peloswing Jul. 7 at 2:29 PM
$ABBV seeing some large net call premiums today (slightly ITM strikes) 🟢 AbbVie's Tepkinly in combination with Lenalidomide and Rituximab approved by European Commission ☑️
0 · Reply
HydrogenH2
HydrogenH2 Jul. 7 at 1:59 PM
$JNJ $ABBV I'm taking 50% profits on both !! Thanks USA !!
0 · Reply
biolover
biolover Jul. 7 at 1:49 PM
$LLY $VKTX on the hands of $ABBV I beleive partnership is happening soon. This dyslocatuon in obesity market can’t continue forever. Not all managments as blind as $MRK and $JNJ
0 · Reply
Quantumup
Quantumup Jul. 7 at 11:16 AM
Truist⬆️ $PTGX's PT to $145 and said ~~ We reiterate our Buy rating of PTGX as we continue to be bullish on broader Icotyde commercial opportunity. $JNJ TAK $ABBV ALMS BMY ABVX Truist added—Johnson & Johnson (JNJ, NR) commentary on Icotyde continues to indicate 1) rapid access and uptake for the drug in Psoriasis; 2) strong KOL enthusiasm driven by label strength, & 3) comments around Ico potential to be "one of their biggest products ever", raising overall peak sales estimates beyond $10B. We have updated our model to reflect slightly increased market share of Icotyde in PsO; new PT is $145/sh vs. $121 prev. Additionally, we provide our perspective on PN-881 with focus on Ph2 start YE26.
0 · Reply
IndyOne
IndyOne Jul. 7 at 10:51 AM
$MRNA The top 12 companies hiring in biopharma now Moderna - YES!!! Along with $AMGN , $ABBV , and $LLY . Hiring surge to support recently announced commercialization plan. V940, mRNA-1010, COMBO ... big. Flu vaccine alone is $10 billion a year run rate. Growing to $15 billion in 5 years. Google advantages of mRNA-1010 over egg based old time vaccine. https://www.biospace.com/career-advice/the-top-12-companies-hiring-in-biopharma-now
0 · Reply
EarlyBirdEmail
EarlyBirdEmail Jul. 7 at 10:45 AM
$RIVN $ABBV $CRNX $VRTX Rivian Automotive fell 9.3% in after-hours trading on Monday, as surprise revenue growth was overshadowed by a new share dilution concern. https://www.earlybird.email/p/rivian-shares-drop-on-dilution-despite-revenue-beat-2026
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 7 at 6:02 AM
$SLS 80th EVENT PR and Ensuing Share Price Launch is Now Imminent. -- the Topline Phase 3 Registrational Results give Gps the FDA Green light to treat upwards of 50,000 AML Remission Patients each year $280K Rev Per Patient - Compounded 5 year Dosing - Top Line Results will give Gps the FDA green light to Generate TENS of BIllions of Dollars in REAL REVENUE - that is worth Every Nickel of $40B + to Big Pharma. 10X - 20X + ROI IMMINENT. IDMC UNBLINDED ACTUAL PH 3 MOS AND IR DATA -- Smart Money Knows - which is the MCAP/SHARE PRICE/ CASH on HAND/FUNDS INVESTED are all UP 1,000% + SINCE THEN.... - meanwhile BAT /Aza+VEN FAILED 3 Large Phase 3 Trials conducted by $ABBV - it is not complicated
0 · Reply